Supernus (SUPN) soars 40% after it receives tentative FDA approval for its Trokendi XR treatment for epilepsy. Final authorization is conditional on Supernus resolving a marketing exclusivity issue regarding a specific pediatric population. The FDA also denies a Citizen's Petition filed in 2011 by Upsher Smith Labs related to its NDA on Trokendi XR
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/